期刊文献+

成人急性髓细胞白血病治疗的成本效益

Analysis of Cost-effectiveness of Treatment in Adult Patients with Acute Myeloid Leukemia
下载PDF
导出
摘要 目的成人急性髓细胞白血病(AML)治疗费用昂贵,不仅是一个临床问题,也是一个社会经济问题。方法从治疗效果,该文探讨了急性髓细胞白血病的治疗花费和不同治疗阶段的成本效益。结果 AML治疗期间院内花费是最大比例的治疗支出,接受干移植是白血病治疗中最重要的花费。在诱导期和巩固期治疗阶段,患者个人情况不同,不同的治疗方案选择,成本效益存在明显的差异,使用集落刺激因子后有助于减少总治疗支出。结论 AML对社会造成的的经济负担十分显著。研究人员需要更多的考察AML治疗与一个国家经济和社会发展水平的相关关系,以便促进医疗保障体系给AML患者带来更多的治疗实惠。 Objective It was not only a clinical problem but also a socio- economic problem for Expensive treatment of adult patients with acute myeloid leukemia (AML). Methods The study discussed the costs and cost - effectiveness in different periods of treatment according to treatment efficacy. Results The hospital costs were the largest proportion of the treatment expenses. Meanwhile it was the most important expenditure for receiving the stem cell transplantation. In the induction and consolidation therapy, there existed significant difference in costeffectiveness for different patients, and different treatment. It was contributed to decrease the total costs for receiving colony - stimulating factor. Conclusion AML caused significant economic burden for the whole society. The researchers should pay more attention to the relation between AML treatment and the socio - economic development. Further it made medical security system bring more treatment benefits to AML patients.
出处 《内蒙古医学杂志》 2014年第1期123-125,共3页 Inner Mongolia Medical Journal
基金 内蒙古自然科学基金项目(2013MS1157)
关键词 急性髓细胞白血病 卫生保健 成本效益 住院费用 巩固治疗 acute myeloid leukemia consolidation therapy
  • 相关文献

参考文献14

  • 1杨永梅.公平视角下的全国儿童大病医疗保障制度研究[J].学术交流,2009(11):141-143. 被引量:4
  • 2Tennvall GR, Persson U, Nilsson B. The economic costs of acute myeIoid leukemia in Sweden[J ]. Int J Tecbaxol Assess Health Care, 1994, 10:683 - 94.
  • 3Uyl - de Groot CA, Gelderblom- den I-lartog J, Huijgens PC, et al. Costs of diagnosis, treatment, and follow up of patients with acute myeloid leukemia in the Netherlands[J ]. J Hematother Stem Cell Res, 2001, 10:187 - 92.
  • 4Menzin J, Lang K, Earle CC, et al. The outcomes and costs of a- cute myeloid leukemia among the elderly[J]. Arch Intern Med, 2002, 162(14):1 597-1 603.
  • 5郭代红,张志萍,朱秀美,王波,任浩洋,刘敏超,郝珍.急性非淋巴性白血病的化疗药物利用及成本分析[J].中国药学杂志,2003,38(2):143-144. 被引量:1
  • 6Yu YB, Gau JP, You JY, et al. Cost- effectiveness of postrem- ission intensive therapy in paticmts with acute leukemia[J ]. Ann Oncol, 2007, 18:529 - 34.
  • 7钱思轩,李建勇,吴汉新,陆化,仇红霞,陈丽娟,卢瑞南,徐卫,盛瑞兰.标准剂量去甲氧柔红霉素联合阿糖胞苷持续静脉点滴治疗急性髓系白血病[J].中国实验血液学杂志,2009,17(1):209-213. 被引量:23
  • 8Huang BT, Wang Y, Du OF, et al. Analysis of efficacy and cost - effectiveness of high - dose arabinoside versus daunorubicin chemotherapy in older adult patients with acute myeloid leukemia by cytogenetic risk profile: retrospective review from China[J ]. Int J Hernatol, 2011, 93:474 - 81.
  • 9Mandelli F, Vignetti M, Suciu S, et al. Daunorubicin versus mi- toxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the E- OR'F(] and GIMEMA Groups Study AML - 10[J]. J Clin Oncol, 2009, 27:5 397 - 5 403.
  • 10van Agthoven M, Groot MT, Verdonck LF, et al. Cost analysis of HLA- identical sibling and voluntary unrelated allogeneic bone marrow and peripheral blood stem cell transplantation in adults with acute myelocytic leukaaaia or acute lympboblastic leukaemia [J]. Bone Marrow Transplant, 2002;30:243 - 51.

二级参考文献26

  • 1于江,徐光.基本公共服务均等化:研究综述与反思[J].消费导刊,2009,0(21):27-33. 被引量:1
  • 2唐耀年 应大明 刘斌清.大剂量阿糖胞苷在ANLL患儿体内的药物动力学[J].中华临床药学杂志,2000,9(1):16-16.
  • 3Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol, 2003 ;21:4642 -4649.
  • 4Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 Trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood, 1998 ;92 : 2322 - 2333.
  • 5Berman E, Heller G, Santorsa J, et al. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood, 1991 ;77 : 1666 -1674.
  • 6Koistinm P, Raty R, Itala M, et al. Long-term outcome of intensive chemotherapy for adults with de nono acute myeloid leukemia (AML) : the nationwide AML-92 study by the Finnish Leukaemia Group. Eur J Haematol, 2007 ;78:477 -486.
  • 7No authors listed. A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia. AML Collaborative Group. Br J Haematol, 1998 ;103:100 - 109.
  • 8Flasshove M, Meusers P, Schutte J, et al. Long-term survival after induction therapy with idarubicin and cytosine arabinoside for de novo acute myeloid leukemia. Ann Hematol, 2000 ;79:533 -542.
  • 9Janet Currie. Child Health In Developed Countries. Handbook Of Health Economics[ M ]. Harvard University: 2000:1062.
  • 102000年世界卫生报告[R].北京:人民卫生出版社,2000:26-30.

共引文献35

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部